carbamazepine has been researched along with Developmental Disabilities in 20 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The developmental quotient (DQ) was lower in children exposed to carbamazepine (CBZ) (n = 50) than in children born to women without epilepsy (n = 79); mean difference (MD) of -5." | 4.90 | Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. ( Adab, N; Bromley, R; Greenhalgh, J; Marson, AG; McKay, AJ; Sanniti, A; Tudur Smith, C; Weston, J, 2014) |
| "The study comprised 40 children and adolescents with idiopathic epilepsy on either valproate or carbamazepine." | 3.76 | Growth hormone levels in children and adolescents with epilepsy. ( Al-Badani, AK; Aly, GS; El-Khayat, HA; Mamdouh, RM; Mohamed, EI; Tomoum, HY, 2010) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "To compare pregnancy outcome prospectively after phenytoin and carbamazepine monotherapy with outcome in matched mother-child pairs exposed to nonteratogens to evaluate the relative fetal safety of these drugs." | 3.69 | Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. ( Ashby, P; Czuchta, D; Einarson, T; Gardner, HA; Gladstone, D; Gladstone, R; Nulman, I; Rovet, J; Scolnik, D; Weksberg, R, 1994) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "For patients with mental retardation or developmental delay, 25(OH)D3 levels were lower than the levels in patients with normal intelligence quotient levels (p=0." | 1.40 | Vitamin D levels in children and adolescents with antiepileptic drug treatment. ( Baek, JH; Eun, BL; Kim, GH; Kim, MK; Seo, YH, 2014) |
| "The paroxysmal dyskinesias are a heterogeneous group of movement disorders." | 1.35 | Oxcarbazepine use in paroxysmal kinesigenic dyskinesia: report on four patients. ( Chillag, KL; Deroos, ST, 2009) |
| "There were 73 children with seizures, 80% of whom had a greater than 50% reduction in seizure frequency following the start of simple anticonvulsant medication." | 1.32 | A review of neurological disorders presenting at a paediatric neurology clinic and response to anticonvulsant therapy in Gambian children. ( Allen, S; Burton, KJ, 2003) |
| "Physicians treating epilepsy must be aware that CBZ can exacerbate seizures, and cause developmental regression in children." | 1.30 | Seizure exacerbation and developmental regression with carbamazepine. ( Nagarajan, L; Prasad, AN; Stefanelli, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daugaard, CA | 1 |
| Pedersen, L | 1 |
| Sun, Y | 1 |
| Dreier, JW | 1 |
| Christensen, J | 1 |
| Cherian, A | 1 |
| Jabeen, SA | 1 |
| Kandadai, RM | 1 |
| Iype, T | 1 |
| Moturi, P | 1 |
| Reddy, M | 1 |
| Kanikannan, MA | 1 |
| Borgohain, R | 1 |
| Padmanabhan, S | 1 |
| Baek, JH | 1 |
| Seo, YH | 1 |
| Kim, GH | 1 |
| Kim, MK | 1 |
| Eun, BL | 1 |
| Verrotti, A | 1 |
| Scaparrotta, A | 1 |
| Cofini, M | 1 |
| Chiarelli, F | 1 |
| Tiboni, GM | 1 |
| Bromley, R | 1 |
| Weston, J | 1 |
| Adab, N | 2 |
| Greenhalgh, J | 1 |
| Sanniti, A | 1 |
| McKay, AJ | 1 |
| Tudur Smith, C | 1 |
| Marson, AG | 1 |
| Chillag, KL | 1 |
| Deroos, ST | 1 |
| Meador, KJ | 2 |
| Baker, GA | 2 |
| Browning, N | 1 |
| Clayton-Smith, J | 3 |
| Combs-Cantrell, DT | 1 |
| Cohen, M | 1 |
| Kalayjian, LA | 1 |
| Kanner, A | 1 |
| Liporace, JD | 1 |
| Pennell, PB | 1 |
| Privitera, M | 1 |
| Loring, DW | 2 |
| El-Khayat, HA | 1 |
| Aly, GS | 1 |
| Tomoum, HY | 1 |
| Mamdouh, RM | 1 |
| Al-Badani, AK | 1 |
| Mohamed, EI | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Morrow, J | 1 |
| Nelson, J | 1 |
| Blumkin, L | 1 |
| Suls, A | 1 |
| Deconinck, T | 1 |
| De Jonghe, P | 1 |
| Linder, I | 1 |
| Kivity, S | 1 |
| Dabby, R | 1 |
| Leshinsky-Silver, E | 1 |
| Lev, D | 1 |
| Lerman-Sagie, T | 1 |
| Verhoeven, WM | 1 |
| Egger, JI | 1 |
| Cohen-Snuijf, R | 1 |
| Kant, SG | 1 |
| de Leeuw, N | 1 |
| Bromley, RL | 1 |
| Mawer, GE | 1 |
| Briggs, M | 1 |
| Cheyne, C | 1 |
| García-Fiñana, M | 1 |
| Kneen, R | 1 |
| Lucas, SB | 1 |
| Shallcross, R | 1 |
| Burton, KJ | 1 |
| Allen, S | 1 |
| Kini, U | 1 |
| Vinten, J | 1 |
| Fryer, A | 1 |
| Piantino, JA | 1 |
| Torres, A | 1 |
| Scolnik, D | 1 |
| Nulman, I | 1 |
| Rovet, J | 1 |
| Gladstone, D | 1 |
| Czuchta, D | 1 |
| Gardner, HA | 1 |
| Gladstone, R | 1 |
| Ashby, P | 1 |
| Weksberg, R | 1 |
| Einarson, T | 1 |
| Jeret, JS | 1 |
| Thompson, WO | 1 |
| Prasad, AN | 1 |
| Stefanelli, M | 1 |
| Nagarajan, L | 1 |
| Rosenberg, DR | 1 |
| Crowner, S | 1 |
| Thomas, C | 1 |
| Gourash, L | 1 |
3 reviews available for carbamazepine and Developmental Disabilities
| Article | Year |
|---|---|
Developmental neurotoxicity and anticonvulsant drugs: a possible link.
Topics: Animals; Anticonvulsants; Breast Feeding; Carbamazepine; Cognition Disorders; Developmental Disabili | 2014 |
Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child.
Topics: Age Factors; Anticonvulsants; Carbamazepine; Child; Developmental Disabilities; Epilepsy; Female; Hu | 2014 |
Psychosis and idiopathic precocious puberty in two 7-year-old boys.
Topics: Attention Deficit Disorder with Hyperactivity; Body Height; Carbamazepine; Child; Developmental Disa | 1992 |
17 other studies available for carbamazepine and Developmental Disabilities
| Article | Year |
|---|---|
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
Epilepsy with myoclonic absences in siblings.
Topics: Anticonvulsants; Carbamazepine; Child; Developmental Disabilities; Electroencephalography; Epilepsie | 2014 |
Vitamin D levels in children and adolescents with antiepileptic drug treatment.
Topics: Adolescent; Anticonvulsants; Bone Density; Bone Diseases, Metabolic; Carbamazepine; Child; Child, Pr | 2014 |
Oxcarbazepine use in paroxysmal kinesigenic dyskinesia: report on four patients.
Topics: Adolescent; Age of Onset; Anti-Dyskinesia Agents; Carbamazepine; Child; Developmental Disabilities; | 2009 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
Growth hormone levels in children and adolescents with epilepsy.
Topics: Adolescent; Anthropometry; Body Weight; Carbamazepine; Chi-Square Distribution; Child; Developmental | 2010 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Neonatal seizures associated with a severe neonatal myoclonus like dyskinesia due to a familial KCNQ2 gene mutation.
Topics: Adult; Anticonvulsants; Carbamazepine; Developmental Disabilities; Dyskinesias; Electroencephalograp | 2012 |
Phelan-McDermid syndrome: clinical report of a 70-year-old woman.
Topics: Aged; Butyrophenones; Carbamazepine; Carrier Proteins; Choline Kinase; Chromosome Deletion; Chromoso | 2013 |
The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Child; Child Development Disorders, Per | 2013 |
A review of neurological disorders presenting at a paediatric neurology clinic and response to anticonvulsant therapy in Gambian children.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Developmental Disabilities; Fem | 2003 |
Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anthropometry; Anticonvulsants; Carbamazepine; Child; Child | 2006 |
Myoclonic seizures in a patient with Charcot-Marie-tooth disease.
Topics: Anticonvulsants; Carbamazepine; Charcot-Marie-Tooth Disease; Child; Developmental Disabilities; Drug | 2007 |
Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy.
Topics: Carbamazepine; Case-Control Studies; Child; Cognition; Developmental Disabilities; Female; Humans; I | 1994 |
Neurodevelopment after in utero exposure to phenytoin and carbamazepine.
Topics: Carbamazepine; Child; Developmental Disabilities; Female; Humans; Phenytoin; Pregnancy; Prenatal Exp | 1994 |
Neurodevelopment after in utero exposure to phenytoin and carbamazepine.
Topics: Carbamazepine; Child; Developmental Disabilities; Female; Humans; Phenytoin; Pregnancy; Prenatal Exp | 1994 |
Seizure exacerbation and developmental regression with carbamazepine.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Devel | 1998 |